Saxagliptin vs Trelagliptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
Saxagliptin · Onglyza
Rights held by AstraZeneca and partners; US product discontinued
NCT00121667 · Phase 3 · completed
Large randomized, double-blind, placebo-controlled phase 3 trial (743 treated participants across three saxagliptin doses and one placebo arm, all on background metformin). The primary endpoint was change from baseline in hemoglobin A1c at Week 24, an accepted hard glycemic measure for type 2 diabetes, and every saxagliptin dose showed a statistically significant improvement versus placebo (adjusted differences of -0.73, -0.83, and -0.72 percentage points, each p<0.0001). Because the trial was adequately powered, double-blind, and placebo-controlled, and the primary comparison was met, this is strong evidence for saxagliptin's efficacy.
Next expected readout: February 2027 · NCT02969798 (registry estimate)
Reported efficacy
Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Baseline, Week 24): Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg + Metformin — Baseline Mean: 8.08 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: -0.59 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 5 mg + Metformin — Baseline Mean: 8.07 percentage of glycosylated hemoglobins (Standard Error 0.06); Adjusted Mean Change from Baseline: -0.69 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 10 mg + Metformin — Baseline Mean: 7.98 percentage of glycosylated hemoglobins (Standard Error 0.08); Adjusted Mean Change from Baseline: -0.58 percentage of glycosylated hemoglobins (Standard Error 0.07) vs Placebo+ Metformin — Baseline Mean: 8.06 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: 0.13 percentage of glycosylated hemoglobins (Standard Error 0.07) (met)
Result source: NCT00121667
Trelagliptin · Zafatek
Marketed by Teijin and partners
NCT01431807 · Phase 3 · completed
This was a single-group, open-label study with no randomization, blinding, or comparator arm, despite enrolling 680 participants. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2026 · NCT07073768 (registry estimate)
Reported efficacy
Change From Baseline in HbA1c at the End of Treatment Period I (Baseline (Week 0) and end of Treatment Period I (Up to Week 12)); Number of Participants Who Had One or More Treatment Emergent Adverse Event (TEAE) Before the Start of Study Drug Administration in Treatment Period II (Up to Week 12); Number of Participants Who Had One or More TEAE Occurred After 1st Dose of Trelagliptin 25 mg Tablet (Up to Week 54): Change From Baseline in HbA1c at the End of Treatment Period I (Baseline (Week 0) and end of Treatment Period I (Up to Week 12)): Trelagliptin 25 mg -0.71 Percent HbA1c (Standard Error 0.087) vs Placebo and Trelagliptin 25 mg 0.01 Percent HbA1c (Standard Error 0.089) (met)
Result source: NCT02512068
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Saxagliptin | Trelagliptin |
|---|---|---|
| HbA1c, change | -0.7% vs -0.3%−0.4 vs placeboNCT0075758819 other results
| -0.7% vs 0.0%−0.7 vs placeboNCT025120684 other results
|
| Body weight, change (kg) | -1.9 vs -0.4−1.5 vs placeboNCT016463207 other results
| —Not posted · NCT03940183 |
| HbA1c below 7% | 44.4% vs 16.6%+27.8 vs placeboNCT0012166715 other results
| —Not posted · NCT03940183 |
| Fasting plasma glucose, change | -0.6 vs -0.3−0.2 vs placeboNCT0075758811 other results
| -0.9 vs -0.0−0.9 vs placeboNCT025120683 other results
|
| 3-point MACE (% with event) | 7.4% vs 7.4%±0 vs placeboNCT01107886 | —Not posted · NCT03940183 |
HbA1c, change
- Saxagliptin
- -0.7% vs -0.3%−0.4 vs placeboNCT00757588
19 other results
- 7.1% vs 7.5% NCT00661362
- -0.5% vs -0.2% NCT01619059
- 0.1% vs 0.5% NCT03199053
- -0.8% vs -0.1% NCT01646320
- -0.7% vs -0.1% NCT01128153
- -0.7% vs 0.6% NCT01204775
- -1% vs 0.9% NCT01434186
- -1.4% vs -1.0% NCT02419612
- -1.4% vs -1.1% NCT02284893
- -1.7% vs -1.5% NCT02551874
- -1.0% vs -0.7% NCT02681094
- -0.2% vs -0.7% NCT03199053
- 0.1% vs -0.7% NCT03199053
- -0.8% vs -1.0% NCT02471404
- -1.2% vs -1.0% NCT02471404
- -0.8% vs -0.8% NCT02243176
- -0.8% vs -0.8% NCT02243176
- -0.5% vs -0.4% NCT01006590
- -0.4% vs -0.6% NCT01006603
- Trelagliptin
- -0.7% vs 0.0%−0.7 vs placeboNCT02512068
4 other results
- -0.7% vs 0.0% NCT02512068
- -0.6% vs -0.1% NCT02512068
- -0.5% vs 0.0% NCT02512068
- -0.2% vs 0.1% NCT02512068
Body weight, change (kg)
- Saxagliptin
- -1.9 vs -0.4−1.5 vs placeboNCT01646320
7 other results
- -3.1 vs 0.9 NCT02419612
- -1.9 vs -0.5 NCT02284893
- -1.5 vs 2.1 NCT02551874
- -2.0 vs -0.4 NCT02681094
- -3.5 vs 1.8 NCT02471404
- -3.1 vs 1.8 NCT02471404
- -1.4 vs -2.0 NCT02243176
- Trelagliptin
- —Not posted · NCT03940183
HbA1c below 7%
- Saxagliptin
- 44.4% vs 16.6%+27.8 vs placeboNCT00121667
15 other results
- 41.1% vs 23.9% NCT00121641
- 43.5% vs 16.6% NCT00121667
- 37.9% vs 23.9% NCT00121641
- 22.1% vs 13.3% NCT00918879
- 45.8% vs 28.8% NCT00698932
- 37.1% vs 16.6% NCT00121667
- 35% vs 23.9% NCT00121641
- 37.5% vs 24.2% NCT00885378
- 21.3% vs 10% NCT03199053
- 36.7% vs 13.3% NCT01646320
- 21.4% vs 11.7% NCT02419612
- 44.3% vs 34.3% NCT02419612
- 37.3% vs 25.1% NCT02284893
- 37.2% vs 26.1% NCT00960076
- 38.3% vs 41.5% NCT02243176
- Trelagliptin
- —Not posted · NCT03940183
Fasting plasma glucose, change
- Saxagliptin
- -0.6 vs -0.3−0.2 vs placeboNCT00757588
11 other results
- -0.5 vs -0.3 NCT01619059
- 0.1 vs 0.2 NCT03199053
- -1.8 vs -0.3 NCT01646320
- -0.3 vs 0.1 NCT01128153
- -1.8 vs -0.6 NCT02284893
- -2.4 vs -1.0 NCT03199053
- -0.6 vs -1.0 NCT03199053
- -1.6 vs -1.5 NCT02471404
- -0.7 vs -1.3 NCT01006603
- -2.1 vs -1.5 NCT02471404
- -1.0 vs -1.0 NCT02243176
- Trelagliptin
- -0.9 vs -0.0−0.9 vs placeboNCT02512068
3 other results
- -0.7 vs -0.2 NCT02512068
- -0.6 vs -0.1 NCT02512068
- -0.7 vs 0.1 NCT02512068
3-point MACE (% with event)
- Saxagliptin
- 7.4% vs 7.4%±0 vs placeboNCT01107886
- Trelagliptin
- —Not posted · NCT03940183
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Saxagliptin: 4 of 4 rows · Trelagliptin: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Saxagliptin | Trelagliptin |
|---|---|---|
| Dropout rate | 22.7%10 mga NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 43 more results25.1%5 mg NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 22.9%2.5 mg NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 29.6%10 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 35.8%5 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 28.4%2.5 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 0% NCT02024477 · Phase 4 · registry result, not featured evidence 10.5%10mg NCT02471404 · Phase 4 · registry result, not featured evidence 4.5%5mg and 10mg NCT02471404 · Phase 4 · registry result, not featured evidence · combination 5.7% NCT02243176 · Phase 4 · registry result, not featured evidence 17.1% NCT01608724 · Phase 4 · registry result, not featured evidence 2.4% NCT01107886 · Phase 4 · registry result, not featured evidence 19.7%5 mg NCT01006603 · Phase 4 · registry result, not featured evidence 19% NCT01006590 · Phase 4 · registry result, not featured evidence · add on —5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —5 mg NCT03199053 · Phase 3 · registry result, not featured evidence · combination —2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence 5.7%Saxagliptin NCT03199053 · Phase 3 · registry result, not featured evidence · background therapy 7.5%dapagliflozin 10 mg, saxagliptin 5 mg NCT02419612 · Phase 3 · registry result, not featured evidence 8.6% NCT02551874 · Phase 3 · registry result, not featured evidence · combination 12.6% NCT02681094 · Phase 3 · registry result, not featured evidence · add on 8.2% NCT02284893 · Phase 3 · registry result, not featured evidence · combination 25% NCT01204775 · Phase 3 · registry result, not featured evidence 0% NCT01434186 · Phase 3 · registry result, not featured evidence —5 mg QD NCT02104804 · Phase 3 · registry result, not featured evidence · combination 6.8%Saxagliptin Plus Insulin NCT02104804 · Phase 3 · registry result, not featured evidence · combination —DAPA + SAXA + MET NCT01646320 · Phase 3 · registry result, not featured evidence · combination 7.5%Dapa+Saxa+Met NCT01646320 · Phase 3 · registry result, not featured evidence · combination 7.2%5 mg NCT01619059 · Phase 3 · registry result, not featured evidence · combination — NCT01606007 · Phase 3 · registry result, not featured evidence · combination 12.4% NCT01128153 · Phase 3 · registry result, not featured evidence 5.8% NCT00960076 · Phase 3 · registry result, not featured evidence · combination 61.4% NCT00575588 · Phase 3 · registry result, not featured evidence · combination 5.6%5 mg NCT00918879 · Phase 3 · registry result, not featured evidence 4.3%5 mg + Metformin XR 1500 mg NCT00918138 · Phase 3 · registry result, not featured evidence · combination 11.8%5 mg NCT00757588 · Phase 3 · registry result, not featured evidence · combination 50.6% NCT00614939 · Phase 3 · registry result, not featured evidence 10.8%2.5 mg NCT00885378 · Phase 3 · registry result, not featured evidence · combination 15%5 mg NCT00374907 · Phase 3 · registry result, not featured evidence 7.7%5 mg NCT00698932 · Phase 3 · registry result, not featured evidence 10.2%5 mg NCT00661362 · Phase 3 · registry result, not featured evidence · combination | 21.8%25 mgb NCT02512068 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3 show 1 more result0% NCT03014479 · Phase 4 · registry result, not featured evidence |
| Discontinued due to AEs | 2.8%10 mga NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 43 more results3.1%5 mg NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.6%2.5 mg NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 4.1%10 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.8%5 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.9%2.5 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 — NCT02024477 · Phase 4 · registry result, not featured evidence 2.2%10mg NCT02471404 · Phase 4 · registry result, not featured evidence 0.3%5mg and 10mg NCT02471404 · Phase 4 · registry result, not featured evidence · combination 0.8% NCT02243176 · Phase 4 · registry result, not featured evidence 2% NCT01608724 · Phase 4 · registry result, not featured evidence — NCT01107886 · Phase 4 · registry result, not featured evidence 4.2%5 mg NCT01006603 · Phase 4 · registry result, not featured evidence 1.4% NCT01006590 · Phase 4 · registry result, not featured evidence · add on —5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —5 mg NCT03199053 · Phase 3 · registry result, not featured evidence · combination —2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —Saxagliptin NCT03199053 · Phase 3 · registry result, not featured evidence · background therapy 0.4%dapagliflozin 10 mg, saxagliptin 5 mg NCT02419612 · Phase 3 · registry result, not featured evidence — NCT02551874 · Phase 3 · registry result, not featured evidence · combination 3.4% NCT02681094 · Phase 3 · registry result, not featured evidence · add on 0.4% NCT02284893 · Phase 3 · registry result, not featured evidence · combination — NCT01204775 · Phase 3 · registry result, not featured evidence — NCT01434186 · Phase 3 · registry result, not featured evidence —5 mg QD NCT02104804 · Phase 3 · registry result, not featured evidence · combination 1.7%Saxagliptin Plus Insulin NCT02104804 · Phase 3 · registry result, not featured evidence · combination —DAPA + SAXA + MET NCT01646320 · Phase 3 · registry result, not featured evidence · combination 1.9%Dapa+Saxa+Met NCT01646320 · Phase 3 · registry result, not featured evidence · combination 0%5 mg NCT01619059 · Phase 3 · registry result, not featured evidence · combination — NCT01606007 · Phase 3 · registry result, not featured evidence · combination 0.8% NCT01128153 · Phase 3 · registry result, not featured evidence 0.7% NCT00960076 · Phase 3 · registry result, not featured evidence · combination 2.6% NCT00575588 · Phase 3 · registry result, not featured evidence · combination —5 mg NCT00918879 · Phase 3 · registry result, not featured evidence —5 mg + Metformin XR 1500 mg NCT00918138 · Phase 3 · registry result, not featured evidence · combination 2%5 mg NCT00757588 · Phase 3 · registry result, not featured evidence · combination 5.9% NCT00614939 · Phase 3 · registry result, not featured evidence —2.5 mg NCT00885378 · Phase 3 · registry result, not featured evidence · combination —5 mg NCT00374907 · Phase 3 · registry result, not featured evidence 0%5 mg NCT00698932 · Phase 3 · registry result, not featured evidence 1.8%5 mg NCT00661362 · Phase 3 · registry result, not featured evidence · combination | 14.5%25 mgb NCT02512068 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3 show 1 more result0% NCT03014479 · Phase 4 · registry result, not featured evidence |
| Serious AEs | 12.2%10 mga NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 43 more results14.1%5 mg NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 12%2.5 mg NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 9.2%10 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 17%5 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 10.8%2.5 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 4.8% NCT02024477 · Phase 4 · registry result, not featured evidence 12.5%10mg NCT02471404 · Phase 4 · registry result, not featured evidence 7.1%5mg and 10mg NCT02471404 · Phase 4 · registry result, not featured evidence · combination 2.1% NCT02243176 · Phase 4 · registry result, not featured evidence 1.8% NCT01608724 · Phase 4 · registry result, not featured evidence 25.5% NCT01107886 · Phase 4 · registry result, not featured evidence 11.4%5 mg NCT01006603 · Phase 4 · registry result, not featured evidence 4.1% NCT01006590 · Phase 4 · registry result, not featured evidence · add on 0%5 mg NCT03199053 · Phase 3 · registry result, not featured evidence 3.8%5 mg NCT03199053 · Phase 3 · registry result, not featured evidence 0%5 mg NCT03199053 · Phase 3 · registry result, not featured evidence · combination 2.3%2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence 1.6%2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence 4.9%2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —Saxagliptin NCT03199053 · Phase 3 · registry result, not featured evidence · background therapy 12.8%dapagliflozin 10 mg, saxagliptin 5 mg NCT02419612 · Phase 3 · registry result, not featured evidence 6.2% NCT02551874 · Phase 3 · registry result, not featured evidence · combination 2.4% NCT02681094 · Phase 3 · registry result, not featured evidence · add on 3.9% NCT02284893 · Phase 3 · registry result, not featured evidence · combination 0% NCT01204775 · Phase 3 · registry result, not featured evidence 0% NCT01434186 · Phase 3 · registry result, not featured evidence 5.1%5 mg QD NCT02104804 · Phase 3 · registry result, not featured evidence · combination —Saxagliptin Plus Insulin NCT02104804 · Phase 3 · registry result, not featured evidence · combination 4.4%DAPA + SAXA + MET NCT01646320 · Phase 3 · registry result, not featured evidence · combination —Dapa+Saxa+Met NCT01646320 · Phase 3 · registry result, not featured evidence · combination 4.6%5 mg NCT01619059 · Phase 3 · registry result, not featured evidence · combination 1.1% NCT01606007 · Phase 3 · registry result, not featured evidence · combination 2.3% NCT01128153 · Phase 3 · registry result, not featured evidence 0% NCT00960076 · Phase 3 · registry result, not featured evidence · combination 12.6% NCT00575588 · Phase 3 · registry result, not featured evidence · combination 0%5 mg NCT00918879 · Phase 3 · registry result, not featured evidence 2.2%5 mg + Metformin XR 1500 mg NCT00918138 · Phase 3 · registry result, not featured evidence · combination 8.2%5 mg NCT00757588 · Phase 3 · registry result, not featured evidence · combination 27.1% NCT00614939 · Phase 3 · registry result, not featured evidence 1.4%2.5 mg NCT00885378 · Phase 3 · registry result, not featured evidence · combination 5%5 mg NCT00374907 · Phase 3 · registry result, not featured evidence 2.8%5 mg NCT00698932 · Phase 3 · registry result, not featured evidence 2.8%5 mg NCT00661362 · Phase 3 · registry result, not featured evidence · combination | 41.8%25 mgb NCT02512068 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3 show 1 more result1.8% NCT03014479 · Phase 4 · registry result, not featured evidence |
| Most frequent reported AEs | 10 mga influenza 15.5% (placebo 15.1%) nasopharyngitis 15.5% (placebo 14%) headache 13.3% (placebo 12.3%) NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 37 more results5 mg influenza 16.2% (placebo 15.1%) nasopharyngitis 14.7% (placebo 14%) arthralgia 10.5% (placebo 6.7%) NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.5 mg diarrhoea 15.1% (placebo 12.8%) nasopharyngitis 14.6% (placebo 14%) headache 14.1% (placebo 12.3%) NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 10 mg arthralgia 16.3% (placebo 7.4%) headache 16.3% (placebo 16.8%) influenza 15.3% (placebo 6.3%) NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 5 mg upper respiratory tract infection 15.1% (placebo 15.8%) urinary tract infection 13.2% (placebo 8.4%) headache 12.3% (placebo 16.8%) NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.5 mg diarrhoea 13.7% (placebo 8.4%) upper respiratory tract infection 11.8% (placebo 15.8%) influenza 10.8% (placebo 6.3%) NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 5mg and 10mg nasopharyngitis 9.9% NCT02471404 · Phase 4 · registry result, not featured evidence · combination hyperlipidaemia 6.2% hyperlipidaemia 3.7% abdominal distension 1.2% NCT02243176 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 2.7% dizziness 2.6% NCT01608724 · Phase 4 · registry result, not featured evidence diabetes mellitus 6.5% (placebo 8.1%) dizziness 4.5% (placebo 4.2%) hypertension 4.2% (placebo 3.9%) NCT01107886 · Phase 4 · registry result, not featured evidence 5 mg nasopharyngitis 6.4% arthralgia 4.7% diarrhoea 4.2% NCT01006603 · Phase 4 · registry result, not featured evidence hypoglycaemia 6.8% diarrhoea 6.1% nasopharyngitis 5.4% NCT01006590 · Phase 4 · registry result, not featured evidence · add on 5 mg toothache 7.7% (placebo 0%) acne 3.8% (placebo 0%) animal bite 3.8% (placebo 0%) NCT03199053 · Phase 3 · registry result, not featured evidence 5 mg aphthous ulcer 3.8% (placebo 0%) back pain 3.8% (placebo 2.6%) colitis 3.8% (placebo 0%) NCT03199053 · Phase 3 · registry result, not featured evidence 5 mg nasopharyngitis 15.4% (placebo 2.6%) asthma 7.7% (placebo 0%) covid-19 7.7% (placebo 2.6%) NCT03199053 · Phase 3 · registry result, not featured evidence · combination 2.5 mg vitamin d deficiency 4.5% (placebo 6.6%) nausea 3.4% (placebo 0%) urinary tract infection 3.4% (placebo 5.3%) NCT03199053 · Phase 3 · registry result, not featured evidence 2.5 mg influenza 4.9% (placebo 2.6%) bronchitis 1.6% (placebo 0%) chronic sinusitis 1.6% (placebo 0%) NCT03199053 · Phase 3 · registry result, not featured evidence 2.5 mg covid-19 6.6% (placebo 2.6%) upper respiratory tract infection 6.6% (placebo 2.6%) urinary tract infection 4.9% (placebo 5.3%) NCT03199053 · Phase 3 · registry result, not featured evidence dapagliflozin 10 mg, saxagliptin 5 mg urinary tract infection 13.7% upper respiratory tract infection 10.1% headache 7.9% NCT02419612 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 7.7% upper respiratory tract infection 5.2% headache 3.7% NCT02551874 · Phase 3 · registry result, not featured evidence · combination glomerular filtration rate decreased 4.1% pollakiuria 2.4% urinary tract infection 2.4% NCT02681094 · Phase 3 · registry result, not featured evidence · add on nasopharyngitis 7.8% headache 5.6% urinary tract infection 4.3% NCT02284893 · Phase 3 · registry result, not featured evidence · combination oropharyngeal pain 50% (placebo 25%) acne 25% (placebo 0%) cough 25% (placebo 25%) NCT01204775 · Phase 3 · registry result, not featured evidence headache 50% (placebo 0%) abdominal pain upper 25% (placebo 0%) back pain 25% (placebo 0%) NCT01434186 · Phase 3 · registry result, not featured evidence 5 mg QD hypoglycaemia 21.8% (placebo 23.8%) upper respiratory tract infection 2.6% (placebo 4.3%) urinary tract infection 2.6% (placebo 0.9%) NCT02104804 · Phase 3 · registry result, not featured evidence · combination urinary tract infection 9.4% (placebo 10%) influenza 7.5% (placebo 7.5%) headache 6.9% (placebo 8.1%) NCT01646320 · Phase 3 · registry result, not featured evidence · combination 5 mg urinary tract infection 7.2% (placebo 6.8%) headache 5.9% (placebo 7.4%) nasopharyngitis 5.9% (placebo 4.9%) NCT01619059 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 6.2% (placebo 9.4%) diarrhoea 5.4% (placebo 3.9%) hypertension 5.4% (placebo 1.6%) NCT01128153 · Phase 3 · registry result, not featured evidence diarrhoea 5.8% urinary tract infection 5.1% nasopharyngitis 4.3% NCT00960076 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 10.7% diarrhoea 5.8% upper respiratory tract infection 5.8% NCT00575588 · Phase 3 · registry result, not featured evidence · combination 5 mg urinary tract infection 8.4% (placebo 9.4%) NCT00918879 · Phase 3 · registry result, not featured evidence 5 mg + Metformin XR 1500 mg cough 6.5% NCT00918138 · Phase 3 · registry result, not featured evidence · combination 5 mg urinary tract infection 7.6% (placebo 7.9%) nasopharyngitis 6.3% (placebo 6.6%) upper respiratory tract infection 6.3% (placebo 7.3%) NCT00757588 · Phase 3 · registry result, not featured evidence · combination hypoglycaemia 28.2% (placebo 29.4%) anaemia 5.9% (placebo 8.2%) hypertension 5.9% (placebo 5.9%) NCT00614939 · Phase 3 · registry result, not featured evidence 5 mg headache 25% (placebo 18.8%) muscle spasms 25% (placebo 0%) infusion site pain 20% (placebo 12.5%) NCT00374907 · Phase 3 · registry result, not featured evidence 5 mg upper respiratory tract infection 6.3% (placebo 7.7%) NCT00698932 · Phase 3 · registry result, not featured evidence 5 mg upper respiratory tract infection 6.7% (placebo 4.5%) NCT00661362 · Phase 3 · registry result, not featured evidence · combination | 25 mgb nasopharyngitis 43.6% (placebo 33.3%) fall 21.8% (placebo 10.4%) hypoglycaemia 21.8% (placebo 14.6%) NCT02512068 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3 show 1 more resultviral upper respiratory tract infection 3.6% NCT03014479 · Phase 4 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 38 of these studies.
- bPopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Saxagliptin
show 8 more results
show 6 more results
show 15 more results
show 3 more results
show 4 more results
show 2 more results
show 7 more results
show 2 more results
show 1 more result
+ 48 further endpoints in the CSV export.
Trelagliptin
show 2 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Saxagliptin's landscape · Trelagliptin's landscape